drugset / Trial / NCT02503176

An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

NCT02503176 ↗

Phase 3 Terminated Kissei Pharmaceutical Co., Ltd.

Summary

The purpose of this study is to evaluate of the long-term safety and efficacy of KCT-0809 in dry eye patients with Sjögren's syndrome.

Timeline

Start
—
Primary completion
2017-05-29
Completion
—

Outcome

Outcome not reported

Stopped: “Discontinuation of the development”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ozagrel Small molecule — —

Indications